Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2021

View Archived Issues

Phase I trial shows diagnostic potential of 64Cu-SAR-bombesin PET/CT in patients with breast cancer

New mouse model recapitulates the pancreatic features of human MODY5

First patient dosed in phase I/II study of CFT-7455 in hematologic malignancies

Positive topline data from phase IIa LIFT study of TERN-101 in NASH

Sirtuin affects cardiac lipotoxicity via secondary mechanism

Celastrol-loaded NPs induce selective apoptosis of macrophages and osteoclasts in arthritic joints

IL1RAP is a key driver of metastasis and a potential immunotherapy target in Ewing sarcoma

Janssen Pharmaceutica discloses new Mcl-1 inhibitors

SIRT6 is a potential therapeutic target to preserve healthy aging and delay the onset of frailty

Suven Life Sciences patents prodrugs of abiraterone for cancer

Senda Biosciences identifies new AhR antagonists

Roche synthesizes muscarinic M4 receptor PAMs

University of Utah divulges TRPV4 antagonists

First-in-human data presented for the anti-CD47 MAb AK-117

BT-200: prolonging half-life of vWF

YL-13027 demonstrates safety and preliminary activity in patients with solid tumors

Topline phase Ib data reported on RPT-193 in atopic dermatitis

Cocrystal's CDI-45205 shows in vitro activity against SARS-CoV-2 and variants

Novadip reports phase I data on first-generation autologous cell-based osteogenic product NVD-001

Exelixis and Bristol Myers Squibb agree to study XL-092 with immuno-oncology therapies

G1 Therapeutics initiates phase II trial of Cosela in metastatic bladder cancer

FDA clears IND for lisaftoclax for ER-positive breast cancer and other solid tumors

Mindset reports first preclinical psychedelic benchmark data from COPE program

EyeGate begins phase II proof-of-concept study of PP-001 for ocular surface inflammation

XWPharma reports phase I data on XW-10172 for sleep disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...